Sm Biomed Sdn Bhd, based in Malaysia, is a pharmaceutical company.
One of their notable products is ERYTHROMYCIN ETHYLSUCCINATE USP, with a corresponding US DMF Number 31754.
Remarkably, this DMF maintains an Active status since its submission on September 08, 2017, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of September 21, 2017, and payment made on August 10, 2017, indicating their dedication to facilitating drug approvals, Categorized as Type II